Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticlePROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM “BIOLOGIC EFFECTS OF LIGHT” (Homburg/Saar, Germany)R

Vitamin D and Mortality

STEFAN PILZ, MARTIN GRÜBLER, MARTIN GAKSCH, VERENA SCHWETZ, CHRISTIAN TRUMMER, BRÍAIN Ó. HARTAIGH, NICOLAS VERHEYEN, ANDREAS TOMASCHITZ and WINFRIED MÄRZ
Anticancer Research March 2016, 36 (3) 1379-1387;
STEFAN PILZ
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
2Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stefan.pilz@chello.at
MARTIN GRÜBLER
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
3Swiss Cardiovascular Center Bern, Department of Cardiology, Bern University Hospital, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARTIN GAKSCH
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VERENA SCHWETZ
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTIAN TRUMMER
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRÍAIN Ó. HARTAIGH
4Department of Radiology, NewYork-Presbyterian Hospital and the Weill Cornell Medical College, New York, NY, U.S.A.
5Department of Internal Medicine/Geriatrics, Yale School of Medicine, Adler Geriatric Center, New Haven, CT, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLAS VERHEYEN
6Department of Cardiology, Medical University of Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREAS TOMASCHITZ
6Department of Cardiology, Medical University of Graz, Graz, Austria
7Specialist Clinic of Rehabilitation PV Bad Aussee, Bad Aussee, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WINFRIED MÄRZ
8Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
9Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany
10Synlab Academy, Synlab Laboratory Services GmbH, Mannheim, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

In this narrative review, we aim to summarize and discuss the current evidence linking vitamin D and mortality. Low 25-hydroxyvitamin D [25(OH)D] concentrations are associated with an increased risk of mortality. This has been shown in different cohort studies including general populations, as well as various patient cohorts. Some single-study results and meta-analyses indicate that the shape of the relationship between 25(OH)D and mortality follows a U- or a reverse J-shaped curve. Interassay and laboratory differences are, however, a limitation of most previous surveys, and standardization of 25(OH)D measurements is needed for future investigations. Apart from observational data, it has been documented in meta-analyses of randomized controlled trials that vitamin D3 supplementation is associated with a moderate, yet statistically significant, reduction in mortality. This latter finding must be interpreted in light of some limitations such as incomplete follow-up data, but such a reduction of mortality with vitamin D3 supplementation as the finding of meta-analyses of randomized controlled trials strongly argues for the benefits and, importantly, also the safety of vitamin D.

  • Vitamin D
  • mortality
  • RCT
  • epidemiology
  • 25(OH)D
  • review

Vitamin D deficiency is recognized as a public health problem because low vitamin D levels are common, and may contribute to various adverse health outcomes (1-4). Beneficial effects of vitamin D for skeletal health, i.e. prevention and treatment of rickets and osteomalacia, as well as anti-fracture effects, were considered to be a sufficient basis for guidelines on Dietary Reference Intakes (DRI) and Dietary Reference Values (DRV) for vitamin D in Europe and North America (5-9). Vitamin D deficiency has also been associated with several extraskeletal diseases such as cancer, infections, and cardiovascular, autoimmune and neuropsychiatric diseases (1-5). Importantly, accumulating evidence suggests that vitamin D deficiency might contribute to premature death.

In this narrative review, we aim to summarize and discuss current evidence linking vitamin D and mortality. We start with a brief introduction on vitamin D metabolism, classic vitamin D effects, and current approaches for laboratory measurements and treatment of vitamin D deficiency. Then we present data on the association between serum 25-hydroxyvitamin D [25(OH)D] and mortality, and will also cover genetic data, i.e. Mendelian randomization studies, on this topic. We summarize and discuss current evidence from randomized controlled trials (RCTs) on the effects of vitamin D supplementation on mortality. We also briefly outline data on vitamin D and cause-specific death. Finally, we provide an outlook on ongoing research with regard to overall health implications of vitamin D deficiency and the potential approaches on how to deal with this issue from a public health perspective.

Vitamin D Metabolism and Classic Effects of Vitamin D

The major source for vitamin D is ultraviolet-B (sunlight)-induced vitamin D synthesis in the skin. In detail, the liver-derived precursor of vitamin D, 7-dehydrocholesterol, is converted to vitamin D in the epidermis under the influence of ultraviolet-B radiation. Nutrition usually contains only minor amounts of vitamin D. Transport of vitamin D metabolites in the circulation is mainly performed by its binding to the vitamin D-binding protein (DBP). In the liver, vitamin D is hydroxylated to 25(OH)D, the major circulating vitamin D metabolite that is used to classify vitamin D status. Further 1α-hydroxylation of 25(OH)D results in the formation of 1,25-dihydroxyvitamin D [1,25(OH)2D], the so-called active vitamin D hormone or calcitriol. The kidneys are the major site for 1,25(OH)2D formation but 1α-hydroxylase expression has also been detected in several types of extrarenal cells and organs, suggesting a local tissue production of 1,25(OH)2D that seems to be mainly dependent on substrate availability of circulating 25(OH)D (10). Effects of 1,25(OH)2D are mediated via binding to the vitamin D receptor (VDR) that is expressed in almost all human cells and regulates approximately 3% of the human genome (11).

Assessment of vitamin D status is carried out by measuring serum levels of 25(OH)D. It has, however, been increasingly recognized that significant assay and laboratory differences exist with regard to the measurement of 25(OH)D (12, 13). Therefore, there is an urgent need for further standardization of laboratory methods with initiatives such as the Vitamin D Standardization Program (12, 13). Caution is, however, warranted when comparing 25(OH)D values derived from different laboratories or assays.

Vitamin D effects are required for physiological bone and mineral metabolism, and one of the major effects of vitamin D, also from an evolutionary perspective, is to ensure adequate calcium supply for bone mineralization thereby preventing rickets and osteomalacia (14-16). In meta-analyses of RCTs it has been documented that vitamin D supplementation can significantly reduce fractures (17, 18). Bischoff-Ferrari et al. showed that a daily vitamin D dose of approximately 800 to 2,000 International Units (IU) (20 to 50 μg) per day is required to achieve this anti-fracture effect (17). Vitamin D supplementation is thus a standard treatment for patients suffering from osteoporosis (19). It is still not entirely clear by through pathways vitamin D reduces fractures, but accumulating evidence suggests that fall prevention by vitamin D may, at least partially, be responsible for the anti-fracture effect (19-22).

With regard to guidelines and recommendations for vitamin D intakes and supplementation, there exists controversy in the literature concerning vitamin D doses and target levels for 25(OH)D (6-9, 23-27). 25(OH)D concentrations of 50 nmol/l (divide by 2.496 to convert nmol/l to ng/ml) are, however, widely considered as sufficient, and can be achieved in almost all individuals of the general population, even in absence of sunlight exposure, when supplementing 800 IU (20 μg) vitamin D per day (8, 9). Therefore, when endogenous vitamin D synthesis is absent, e.g. during winter in Germany, vitamin D intake of 800 IU (20 μg) is recommended for the general population (8). Actual vitamin D intake by nutrition and supplements is, however, usually below 200 IU (5 μg) per day in the vast majority of the general population (28-30). Consequently, significant parts of the general population have serum 25(OH)D concentrations below 50 nmol/l (31, 32). When considering the potential public health consequences of vitamin D deficiency, it is of great concern that there is a huge gap between official dietary recommendations and actual intakes of vitamin D. It is, thus, of public health interest to further evaluate whether the proposed involvement of vitamin D in several diseases contributes to premature mortality in vitamin D-deficient individuals.

Vitamin D Status and Mortality

The vast majority of prospective observational studies showed that individuals at the lower end of the 25(OH)D distribution are at significantly increased risk of mortality (33-53). These data have been derived from investigations in the general populations, as well as in various different patient cohorts (33-46). In meta-analyses, the effect estimates for the increase in mortality in individuals with vitamin D deficiency ranged from approximately 40 to 90% when comparing groups with the lowest versus the highest (reference) 25(OH)D levels (34, 41, 43, 44, 47). The largest meta-analysis including 849,412 study participants from 73 cohort studies with 66,511 mortality events was conducted by Chowdhury et al. (44). In that study, the relative risk (RR) [with 95% confidence interval (CI)] for mortality, adjusted for potential risk factors, in the bottom versus the top third of baseline 25(OH)D levels was 1.35 (1.22 to 1.49). Comparing participants with 25(OH)D <25 nmol/l versus those with ≥75 nmol/l, the RR (95% CI) was 1.50 (1.21 to 1.87). Assuming a linear relationship between vitamin D status and mortality, each decrease in 25(OH)D of 25 nmol/l was associated with a 16% (95% CI=8-23%) increase in all-cause mortality. Importantly, the association between 25(OH)D and mortality was similar across various subgroups analyses. The second largest meta-analysis was performed by Garland et al. and included over 500,000 study individuals (47, 53). In that work, the hazard ratio (95% CI) for mortality in participants with 25(OH)D levels ≤22.5 nmol/l compared to those with >75 nmol/l was 1.9 (1.6 to 2.2).

While meta-analyses of epidemiological studies have consistently confirmed that individuals with low 25(OH)D concentrations are at increased risk of mortality, the precise shape of the 25(OH)D–mortality curve is still not entirely clear. Some studies reported on a U- or reverse J-shaped curve for the 25(OH)D and mortality relationship, while others did not (45-53). The reports on U- or reverse J-shaped curves raised the questions of which 25(OH)D levels at the lower (and higher) end are associated with increased mortality, and which levels are optimal. Most observational studies performed their statistical analyses on mortality risk according to a few 25(OH)D groups (e.g. quartiles), and were therefore not adequately designed to evaluate the 25(OH)D–mortality curve in detail. To address this issue, Sempos et al. analyzed 15-year follow-up data of the Third National Health and Nutrition Examination Survey including 15,099 individuals of whom 3,784 died (52). They observed a reverse J-shaped association between 25(OH)D and mortality with a steep upswing for levels below 40 nmol/l. Compared to the reference group with 25(OH)D levels of 75-99 nmol/l, individuals with 25(OH)D concentrations of 120 nmol/l or more were at higher risk of mortality, but the level of statistical significance was only achieved in some statistical models and disappeared in the fully adjusted analyses. In the same work, the lowest mortality risk was observed at levels of 81 nmol/l. In line with this, the meta-analysis by Zittermann et al. in 62,548 individuals of the general population reported the lowest mortality risk for individuals with 25(OH)D serum concentrations ranging from 75-87.5 nmol/l. In that meta-analysis, the 25(OH)D–mortality relationship curve resembled a reverse J-shaped curve (41). There was, however, no statistically significantly increased risk of mortality in individuals with the highest 25(OH)D concentrations, but mortality risk was only estimated up to levels of 112.5 nmol/l (41). While it has been hypothesized that one explanation for the reverse J-shaped curve may be that individuals with high 25(OH)D concentrations started to take vitamin D supplements but were previously vitamin D deficient, it must also be underlined that it is well established that vitamin D can be toxic at very high doses, leading to life-threatening conditions with hypercalcemia and calcification (50, 52-54). Hypercalcemia, as the hallmark of vitamin D intoxication, however, only occurs at 25(OH)D levels above ~375 to 500 nmol/l and thus with extreme overdosing of vitamin D. Considering that 25(OH)D levels up to approximately 125 nmol/l can be considered relatively safe, there is a wide range of 25(OH)D levels, i.e. from 125-375 nmol/l, for which there are insufficient data on whether and by which mechanisms these levels could be harmful.

When reviewing and discussing the 25(OH)D–mortality relationship, it must be acknowledged that a major limitation of most observational studies is the lack of standardization of laboratory measurements of 25(OH)D (12). Caution is therefore warranted when interpreting and discussing absolute 25(OH)D values that are derived from different laboratory methods. Moreover, published meta-analyses are, with the exception of the work by Schöttker et al., limited by using the conventional meta-analysis approach of analyzing literature-based study results (43, 55). Individual participant data (IPD) meta-analyses are superior compared to these classic literature-based meta-analyses as they aim to harmonize data e.g. with regard to grouping, adjustments and statistical approaches of the individual studies (55). Therefore, further IPD meta-analyses on 25(OH)D and mortality are urgently needed that should include studies with standardized 25(OH)D measurements and calculate regression curves for the 25(OH)D–mortality relationship that are not only based on groups (e.g. quartiles) but on IPD data of each single individual.

In addition to these findings on 25(OH)D and mortality, it should also be mentioned that in some, albeit not all, studies, low sunlight exposure and low levels of 1,25(OH)2D have been associated with an increased mortality (56-62). These issues, which extend the scope of our work have been well reported elsewhere (56-62).

Vitamin D Genetics and Mortality

Genome-wide association studies have identified genetic loci that are associated with circulating 25(OH)D concentrations (63, 64). These genetic loci encode genes with relevance for vitamin D synthesis, i.e. for synthesis of vitamin D precursors [7-dehydrocholesterol reductase (DHCR7)] and vitamin D 25-hydroxlyation [cytochrome P450 2R1 (CYP2R1)], as well as for vitamin D metabolism, i.e. for vitamin D transport by DBP [group-specific component (GC)] and 24-hydroxylation (CYP24A1). These genetic variants can be used to conduct Mendelian randomization studies that evaluate whether the genetically determined variation of a risk marker, e.g. 25(OH)D, is associated with outcome (e.g. mortality) (65). Assuming that the genetic variations for 25(OH)D are not associated with confounding factors, Mendelian randomization studies are useful for evaluating whether an association is causal (66, 67). Moreover, the use of such genetic data has the advantage over RCTs that lifelong exposure is tested, whereas RCTs have a limited intervention time. In this context, Afzal et al. performed a Mendelian randomization study to evaluate whether genetically low 25(OH)D levels are associated with increased mortality (68). They included 95,766 White participants of Danish descent and used genetic variants of DHCR7 and CYP2R1 for their study. For plasma 25(OH)D concentrations, each decrease of 20 nmol/l was associated with an adjusted odds ratio for mortality of 1.21 (95% CI=1.11 to 1.31), thus confirming the established association between vitamin D deficiency and increased mortality. Interestingly, for genetically determined 25(OH)D concentrations, each decrease of 20 nmol/l was associated with an odds ratio of 1.30 (95% CI=1.05-1.61). Therefore, there was no significant difference for the association with mortality between the genetically determined and the measured plasma 25(OH)D levels. These findings suggest that the association between low 25(OH)D and mortality may be causal.

Vitamin D Supplementation and Mortality

In addition to the above mentioned observational data, meta-analyses of RCTs have found that vitamin D3 supplementation reduces overall mortality (44, 69-71). In a Cochrane meta-analysis, Bjelakovic et al. included 56 trials with 95,286 study participants (69). In detail, they included RCTs comparing any type of vitamin D supplementation (i.e. vitamin D3, vitamin D2, and active vitamin D or its analogs) versus placebo or no intervention. The study participants of the included trials were, in the majority, older women and the mean treatment duration was 4.4 years. Vitamin D of any type reduced mortality with a risk ratio (95% CI) of 0.97 (0.94 to 0.99), but among the different forms of vitamin D, only vitamin D3 treatment was associated with a significantly reduced mortality and a risk ratio (95% CI) of 0.94 (0.91 to 0.98). Based on this finding, it was further calculated that 150 individuals need to be treated with vitamin D3 over 5 years to prevent one death. There were no significant differences for the effect of vitamin D3 on mortality in various sensitivity/sub-group analyses. Rejnmark et al. (70) and Bolland et al. (71) reported on similar effects of vitamin D on mortality. Chowdury et al. restricted their meta-analysis to randomized trials that supplemented natural vitamin D (vitamin D3 or D2) alone without any concomitant intervention such as e.g. calcium (44). They included 30,716 study participants and found that vitamin D3, but not vitamin D2, reduced mortality significantly, with a risk ratio of 0.89 (95% CI=0.80 to 0.99). Although these findings on vitamin D3 and mortality were statistically significant, it must be noted that due to e.g. incomplete follow-up data of the analyzed RCTs and some other limitations, it is still not entirely clear whether this reflects a true effect. Nevertheless, a reduction in mortality within a background of vitamin D supplementation according to meta-analyses of RCTs provides a strong rationale in favor of the benefits and safety of vitamin D intake. This notion is underlined by a recent RCT in patients in intensive care units (72). In that RCT, Amrein et al. included 492 critically ill patients with 25(OH)D concentrations ≤50 nmol/l who were randomly allocated to vitamin D3 at a dose of 540,000 IU followed by monthly maintenance doses of 90,000 IU vitamin D3 for 5 months or placebo. There was no significant effect on mortality and several other outcomes in the whole study population, but in a pre-specified sub-group analysis of patients with 25(OH)D levels ≤30 nmol/l, hospital mortality was significantly reduced in the vitamin D-supplemented group compared to the placebo-treated group, with a hazard ratio (95% CI) of 0.56 (0.35 to 0.90).

Vitamin D and Specific Causes of Death

While we mainly report on vitamin D and all-cause mortality in this review, it is also important to briefly summarize the literature on specific causes of death, in order to gain more knowledge on the potential pathways and mechanisms that may link vitamin D and fatal events.

In observational studies, low 25(OH)D levels have been associated with increased risk of mortality due to cardiovascular diseases, cancer, respiratory disease, and non-vascular, non-cancer causes (33, 35, 36, 43, 44, 49, 73-76).

In the Mendelian randomization study by Afzal et al. it was reported that the odds ratio (95% CI) for cardiovascular mortality for each decrease of 20 nmol/l in plasma 25(OH)D was 1.13 (1.03 to 1.24), and the respective odds ratio (95% CI) for the genetically determined 25(OH)D levels was 0.77 (0.55 to 1.08) (68). This may suggest that the association between low 25(OH)D and cardiovascular deaths may not be causal. For cancer mortality, the respective odds ratios (95% CI) for each decrease of 20 nmol/l 25(OH)D was 1.10 (1.02 to 1.19) for plasma 25(OH)D and 1.43 (1.02 to 1.99) for genetically determined 25(OH)D. These data argue for causality with regard to the association of vitamin D deficiency and increased cancer mortality.

Meta-analyses of RCTs further support a causal effect of vitamin D on cancer mortality. In the Cochrane meta-analysis by Bjelakovic et al. involving 44,492 study participants from four trials, it was documented that vitamin D3 supplementation statistically significantly reduced cancer mortality, with a risk ratio of 0.88 (95% CI=0.78-0.98). In line with this, Keum et al. also reported in their meta-analysis involving 44,260 participants that the RR for cancer mortality in the vitamin D-treated versus the placebo-treated group was 0.88 (95% CI=0.78-0.98) (77). These findings along with various molecular anticancer effects of vitamin D suggest that vitamin D supplementation may be useful for the prevention of cancer deaths. By contrast, there was no effect in meta-analyses on cancer incidence, suggesting that vitamin D might rather be relevant for the progression than for the initiation of cancer (77-79).

With regard to cardiovascular mortality, there was no significant effect of vitamin D as reported by Bjelakovic et al. (69). Although observational studies highlight vitamin D deficiency as a risk factor for cardiovascular events and strokes, most RCTs did not show any effect of vitamin D on these outcomes (69, 71, 80-83). It must, however, be acknowledged that no published RCT on vitamin D has been designed and statistically powered to assess cardiovascular events. Existing knowledge on the potential role of vitamin D for various other health outcomes have been extensively reviewed elsewhere (1-6, 84, 85).

Outlook and Conclusion

Vitamin D deficiency is a risk factor for increased mortality and meta-analyses of randomized trials suggest that vitamin D3 supplementation may reduce mortality. These data along with the established effects of vitamin D on skeletal health point towards the urgent need to prevent and treat vitamin D deficiency in the general population.

The actual vitamin D intake in the general population is far below the recommended DRI for vitamin D, thus contributing to a relatively high prevalence of vitamin D deficiency. Therefore, there is an urgent need for public health approaches to improve vitamin D status. A ‘healthy lifestyle’ with outdoor activities involving careful and balanced sunlight exposure along with efforts to combat the global burden of obesity would, without any dietary vitamin D interventions, substantially improve 25(OH)D levels in the general population (9, 87-91). Being aware that changing lifestyle is hard to achieve, it is clear that additional efforts are required to increase oral vitamin D intake by diet and/or supplements. A promising approach is vitamin D food fortification that has already been introduced in countries such as Finland and the US. Work such as the EU project ODIN, Food-based Solutions for Optimal Vitamin D Nutrition and Health Throughout the Life Cycle (http://www.odin-vitd.eu/), is currently in progress to further investigate (and hopefully introduce) vitamin D food fortification in general populations throughout the EU (9, 86). Moreover, some expert groups are also suggesting vitamin D supplement intake for groups at high risk of vitamin D deficiency, and a recent study on cost-effectiveness of vitamin D supplementation calculated that treating the elderly UK population with 800 IU vitamin D3 per day would translate into substantial cost-savings through fall prevention (26, 87). Elucidating safe and efficient approaches to eradicate vitamin D deficiency is a challenge for public health authorities and should be a goal with a high priority when considering the potential and the risk–benefit ratio of vitamin D supplementation for improvement of public health and health economics.

Regarding vitamin D research, there are some large ongoing RCTs on vitamin D in the general population that will significantly increase our knowledge on whether general vitamin D supplementation in the older population has an effect on clinical endpoints, including mortality (92, 93). It is, however, of concern that all large RCTs on vitamin D recruited participants regardless of their 25(OH)D levels, thereby increasing the probability of missing beneficial effects of vitamin D supplementation in individuals with low 25(OH)D concentrations. Null effects of such RCTs would definitely argue against major effect sizes but definite answers on whether vitamin D supplementation has relevant effects on mortality outcomes and other clinical endpoints should be derived from RCTs in severely vitamin D-deficient individuals, as this is the target population for vitamin D interventions (92-95).

Acknowledgements

Martin Gaksch is supported by the EU project ODIN (FFood-based Solutions for Optimal Vitamin D Nutrition and Health Throughout the Life Cycle; FP7-KBBE-2013-7-single-stage; Grant agreement no: 613977).

  • Received November 30, 2015.
  • Revision received January 12, 2016.
  • Accepted January 14, 2016.
  • Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Pilz S,
    2. Gaksch M,
    3. Hartaigh BÓ,
    4. Tomaschitz A,
    5. März W
    : Vitamin D in preventive medicine. Anticancer Res 35: 1161-1170, 2015.
    OpenUrlAbstract/FREE Full Text
    1. Pludowski P,
    2. Holick MF,
    3. Pilz S,
    4. Wagner CL,
    5. Hollis BW,
    6. Grant WB,
    7. Shoenfeld Y,
    8. Lerchbaum E,
    9. Llewellyn DJ,
    10. Kienreich K,
    11. Soni M
    : Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality–A review of recent evidence. Autoimmun Rev 12: 976-989, 2013.
    OpenUrlCrossRefPubMed
    1. Zittermann A
    :Vitamin D and cardiovascular disease. Anticancer Res 34: 4641-4648, 2014.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Holick MF
    : Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rosen CJ,
    2. Adams JS,
    3. Bikle DD,
    4. Black DM,
    5. Demay MB,
    6. Manson JE,
    7. Murad MH,
    8. Kovacs CS
    . The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 33: 456-492, 2012.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ross AC,
    2. Manson JE,
    3. Abrams SA,
    4. Aloia JF,
    5. Brannon PM,
    6. Clinton SK,
    7. Durazo-Arvizu RA,
    8. Gallagher JC,
    9. Gallo RL,
    10. Jones G,
    11. Kovacs CS,
    12. Mayne ST,
    13. Rosen CJ,
    14. Shapses SA
    : The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96: 53-58, 2011.
    OpenUrlCrossRefPubMed
    1. Cashman KD,
    2. Kiely M
    : Recommended dietary intakes for vitamin D: Where do they come from, what do they achieve and how can we meet them? J Hum Nutr Diet 27: 434-442, 2014.
    OpenUrlCrossRefPubMed
  5. ↵
    1. German Nutrition Society
    . New reference values for vitamin D. Ann Nutr Metab 60: 241-246, 2012.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Cashman KD
    : Vitamin D: dietary requirements and food fortification as a means of helping achieve adequate vitamin D status. J Steroid Biochem Mol Biol 148: 19-26, 2015.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Höbaus J,
    2. Thiem U,
    3. Hummel DM,
    4. Kallay E
    : Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anticancer Agents Med Chem 13: 20-35, 2013.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Bouillon R,
    2. Carmeliet G,
    3. Verlinden L,
    4. van Etten E,
    5. Verstuyf A,
    6. Luderer HF,
    7. Lieben L,
    8. Mathieu C,
    9. Demay M
    : Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 29: 726-776, 2008.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Sempos CT,
    2. Durazo-Arvizu RA,
    3. Binkley N,
    4. Jones J,
    5. Merkel JM,
    6. Carter GD
    . Developing vitamin D dietary guidelines and the lack of 25-hydroxyvitamin D assay standardization: The ever-present past. J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2015.08.027, 2015.
  10. ↵
    1. Cashman KD,
    2. Kiely M,
    3. Kinsella M,
    4. Durazo-Arvizu RA,
    5. Tian L,
    6. Zhang Y,
    7. Lucey A,
    8. Flynn A,
    9. Gibney MJ,
    10. Vesper HW,
    11. Phinney KW,
    12. Coates PM,
    13. Picciano MF,
    14. Sempos CT
    : Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of the program's potential for national nutrition and health surveys. Am J Clin Nutr 97: 1235-1242, 2013.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Lips P
    : Vitamin D deficiency and secondary hyperpara-thyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22: 477-501, 2001
    OpenUrlCrossRefPubMed
    1. Bouillon R,
    2. Suda T
    : Vitamin D: calcium and bone homeostasis during evolution. Bonekey Rep 3: 480, 2014.
    OpenUrlPubMed
  12. ↵
    1. Shaw DN
    . Prevention and treatment of nutritional rickets. Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2015.10.014, 2015.
  13. ↵
    1. Bischoff-Ferrari HA,
    2. Willett WC,
    3. Orav EJ,
    4. Lips P,
    5. Meunier PJ,
    6. Lyons RA,
    7. Flicker L,
    8. Wark J,
    9. Jackson RD,
    10. Cauley JA,
    11. Meyer HE,
    12. Pfeifer M,
    13. Sanders KM,
    14. Stähelin HB,
    15. Theiler R,
    16. Dawson-Hughes B
    : A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367: 40-49, 2012.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Bolland MJ,
    2. Grey A
    . A case study of discordant overlapping meta-analyses: vitamin D supplements and fracture. PLoS One 9: e115934, 2014.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Kanis JA,
    2. McCloskey EV,
    3. Johansson H,
    4. Cooper C,
    5. Rizzoli R,
    6. Reginster JY,
    7. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO),
    8. the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF)
    . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24: 23-57, 2013.
    OpenUrlCrossRefPubMed
    1. Reid IR,
    2. Bolland MJ,
    3. Grey A
    : Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383: 146-55, 2014.
    OpenUrlCrossRefPubMed
    1. Bolland MJ,
    2. Grey A,
    3. Reid IR
    . Differences in overlapping meta-analyses of vitamin D supplements and falls. J Clin Endocrinol Metab 99: 4265-4272, 2014.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Murad MH,
    2. Elamin KB,
    3. Abu Elnour NO,
    4. Elamin MB,
    5. Alkatib AA,
    6. Fatourechi MM,
    7. Almandoz JP,
    8. Mullan RJ,
    9. Lane MA,
    10. Liu H,
    11. Erwin PJ,
    12. Hensrud DD,
    13. Montori VM
    . Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 96: 2997-3006, 2011.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Holick MF,
    2. Binkley NC,
    3. Bischoff-Ferrari HA,
    4. Gordon CM,
    5. Hanley DA,
    6. Heaney RP,
    7. Murad MH,
    8. Weaver CM,
    9. Endocrine Society
    . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1911-30, 2011.
    OpenUrlCrossRefPubMed
    1. Rosen CJ,
    2. Abrams SA,
    3. Aloia JF,
    4. Brannon PM,
    5. Clinton SK,
    6. Durazo-Arvizu RA,
    7. Gallagher JC,
    8. Gallo RL,
    9. Jones G,
    10. Kovacs CS,
    11. Manson JE,
    12. Mayne ST,
    13. Ross AC,
    14. Shapses SA,
    15. Taylor CL
    : IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 97: 1146-1152, 2012.
    OpenUrlCrossRefPubMed
    1. Holick MF,
    2. Binkley NC,
    3. Bischoff-Ferrari HA,
    4. Gordon CM,
    5. Hanley DA,
    6. Heaney RP,
    7. Murad MH,
    8. Weaver CM
    : Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 97: 1153-1158, 2012.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Brouwer-Brolsma EM,
    2. Bischoff-Ferrari HA,
    3. Bouillon R,
    4. Feskens EJ,
    5. Gallagher CJ,
    6. Hypponen E,
    7. Llewellyn DJ,
    8. Stoecklin E,
    9. Dierkes J,
    10. Kies AK,
    11. Kok FJ,
    12. Lamberg-Allardt C,
    13. Moser U,
    14. Pilz S,
    15. Saris WH,
    16. van Schoor NM,
    17. Weber P,
    18. Witkamp R,
    19. Zittermann A,
    20. de Groot LC
    : Vitamin D: Do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. Osteoporos Int 24: 1567-1577, 2013.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hintzpeter B,
    2. Mensink GB,
    3. Thierfelder W,
    4. Müller MJ,
    5. Scheidt-Nave C
    : Vitamin D status and health correlates among German adults. Eur J Clin Nutr 62: 1079-1089, 2008.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Calvo MS,
    2. Whiting SJ,
    3. Barton CN
    . Vitamin D intake: a global perspective of current status. J Nutr 135: 310-316, 2005.
    OpenUrlAbstract/FREE Full Text
    1. Kiely M,
    2. Black LJ
    . Dietary strategies to maintain adequacy of circulating 25-hydroxyvitamin D concentrations. Scand J Clin Lab Invest Suppl 243: 14-23, 2012.
    OpenUrlPubMed
  21. ↵
    1. Hilger J,
    2. Friedel A,
    3. Herr R,
    4. Rausch T,
    5. Roos F,
    6. Wahl DA,
    7. Pierroz DD,
    8. Weber P,
    9. Hoffmann K
    : A systematic review of vitamin D status in populations worldwide. Br J Nutr 111: 23-45, 2014.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wahl DA,
    2. Cooper C,
    3. Ebeling PR,
    4. Eggersdorfer M,
    5. Hilger J,
    6. Hoffmann K,
    7. Josse R,
    8. Kanis JA,
    9. Mithal A,
    10. Pierroz DD,
    11. Stenmark J,
    12. Stöcklin E,
    13. Dawson-Hughes B
    : A global representation of vitamin D status in healthy populations. Arch Osteoporos 7: 155-172, 2012.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Melamed ML,
    2. Michos ED,
    3. Post W,
    4. Astor B
    : 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168: 1629-1637, 2008.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Schöttker B,
    2. Haug U,
    3. Schomburg L,
    4. Köhrle J,
    5. Perna L,
    6. Müller H,
    7. Holleczek B,
    8. Brenner H
    : Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr 97: 782-793, 2013.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Schöttker B,
    2. Saum KU,
    3. Perna L,
    4. Ordóñez-Mena JM,
    5. Holleczek B,
    6. Brenner H
    : Is vitamin D deficiency a cause of increased morbidity and mortality at older age or simply an indicator of poor health? Eur J Epidemiol 29: 199-210, 2014.
    OpenUrlPubMed
  26. ↵
    1. Pilz S,
    2. März W,
    3. Wellnitz B,
    4. Seelhorst U,
    5. Fahrleitner-Pammer A,
    6. Dimai HP,
    7. Boehm BO,
    8. Dobnig H
    : Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93: 3927-3935, 2008.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Zittermann A,
    2. Kuhn J,
    3. Dreier J,
    4. Knabbe C,
    5. Gummert JF,
    6. Börgermann J
    : Vitamin D status and the risk of major adverse cardiac and cerebrovascular events in cardiac surgery. Eur Heart J 34: 1358-1364, 2013.
    OpenUrlCrossRefPubMed
    1. Pilz S,
    2. Tomaschitz A,
    3. Friedl C,
    4. Amrein K,
    5. Drechsler C,
    6. Ritz E,
    7. Boehm BO,
    8. Grammer TB,
    9. März W
    : Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 26: 3603-3609, 2011.
    OpenUrlCrossRefPubMed
    1. Putz-Bankuti C,
    2. Pilz S,
    3. Stojakovic T,
    4. Scharnagl H,
    5. Pieber TR,
    6. Trauner M,
    7. Obermayer-Pietsch B,
    8. Stauber RE
    : Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int 32: 845-51, 2012.
    OpenUrlPubMed
    1. Thomas GN,
    2. ó Hartaigh B,
    3. Bosch JA,
    4. Pilz S,
    5. Loerbroks A,
    6. Kleber ME,
    7. Fischer JE,
    8. Grammer TB,
    9. Böhm BO,
    10. März W
    : Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Diabetes Care 35: 1158-1164, 2012.
    OpenUrlAbstract/FREE Full Text
    1. Pilz S,
    2. Dobnig H,
    3. Tomaschitz A,
    4. Kienreich K,
    5. Meinitzer A,
    6. Friedl C,
    7. Wagner D,
    8. Piswanger-Sölkner C,
    9. März W,
    10. Fahrleitner-Pammer A
    : Low 25-hydroxyvitamin D is associated with increased mortality in female nursing home residents. J Clin Endocrinol Metab 97: E653-7, 2012.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Zittermann A,
    2. Iodice S,
    3. Pilz S,
    4. Grant WB,
    5. Bagnardi V,
    6. Gandini S
    : Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies Am J Clin Nutr 95: 91-100, 2012.
    OpenUrlAbstract/FREE Full Text
    1. Pilz S,
    2. Iodice S,
    3. Zittermann A,
    4. Grant WB,
    5. Gandini S
    : Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 58: 374-382, 2011.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Schöttker B,
    2. Jorde R,
    3. Peasey A,
    4. Thorand B,
    5. Jansen EH,
    6. Groot Ld,
    7. Streppel M,
    8. Gardiner J,
    9. Ordóñez-Mena JM,
    10. Perna L,
    11. Wilsgaard T,
    12. Rathmann W,
    13. Feskens E,
    14. Kampman E,
    15. Siganos G,
    16. Njølstad I,
    17. Mathiesen EB,
    18. Kubínová R,
    19. Pająk A,
    20. Topor-Madry R,
    21. Tamosiunas A,
    22. Hughes M,
    23. Kee F,
    24. Bobak M,
    25. Trichopoulou A,
    26. Boffetta P,
    27. Brenner H,
    28. Consortium on Health and Ageing
    : Network of Cohorts in Europe and the United States: Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 348: g3656, 2014.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Chowdhury R,
    2. Kunutsor S,
    3. Vitezova A,
    4. Oliver-Williams C,
    5. Chowdhury S,
    6. Kiefte-de-Jong JC,
    7. Khan H,
    8. Baena CP,
    9. Prabhakaran D,
    10. Hoshen MB,
    11. Feldman BS,
    12. Pan A,
    13. Johnson L,
    14. Crowe F,
    15. Hu FB,
    16. Franco OH
    : Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 348: g1903, 2014.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Michaëlsson K,
    2. Baron JA,
    3. Snellman G,
    4. Gedeborg R,
    5. Byberg L,
    6. Sundström J,
    7. Berglund L,
    8. Arnlöv J,
    9. Hellman P,
    10. Blomhoff R,
    11. Wolk A,
    12. Garmo H,
    13. Holmberg L,
    14. Melhus H
    : Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 92: 841-848, 2010.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Amrein K,
    2. Quraishi SA,
    3. Litonjua AA,
    4. Gibbons FK,
    5. Pieber TR,
    6. Camargo CA Jr.,
    7. Giovannucci E,
    8. Christopher KB
    . Evidence for a U-shaped relationship between prehospital vitamin D status and mortality: a cohort study. J Clin Endocrinol Metab 99: 1461-1469, 2014.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Garland CF,
    2. Kim JJ,
    3. Mohr SB,
    4. Gorham ED,
    5. Grant WB,
    6. Giovannucci EL,
    7. Baggerly L,
    8. Hofflich H,
    9. Ramsdell JW,
    10. Zeng K,
    11. Heaney RP
    . Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health 104: e43-50, 2014.
    OpenUrlPubMed
    1. Durup D,
    2. Jørgensen HL,
    3. Christensen J,
    4. Schwarz P,
    5. Heegaard AM,
    6. Lind B
    . A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 97: 2644-2652, 2012.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Durup D,
    2. Jørgensen HL,
    3. Christensen J,
    4. Tjønneland A,
    5. Olsen A,
    6. Halkjær J,
    7. Lind B,
    8. Heegaard AM,
    9. Schwarz P
    : A Reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: The CopD Study. J Clin Endocrinol Metab 100: 2339-2346, 2015.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Grant WB
    . Letter to the Editor: The J-shaped 25-hydroxyvitamin D concentration-cardiovascular disease mortality relation is very likely due to starting vitamin D supplementation late in life. J Clin Endocrinol Metab 100: L49-50, 2015.
    OpenUrlPubMed
    1. Schwarz P
    . Response to the letter by Grant. J Clin Endocrinol Metab 100: L51, 2015
    OpenUrlPubMed
  36. ↵
    1. Sempos CT,
    2. Durazo-Arvizu RA,
    3. Dawson-Hughes B,
    4. Yetley EA,
    5. Looker AC,
    6. Schleicher RL,
    7. Cao G,
    8. Burt V,
    9. Kramer H,
    10. Bailey RL,
    11. Dwyer JT,
    12. Zhang X,
    13. Gahche J,
    14. Coates PM,
    15. Picciano MF
    . Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab 98: 3001-3009, 2013.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Gröber U,
    2. Reichrath J,
    3. Holick MF
    . Live longer with vitamin D? Nutrients 7: 1871-1880, 2015.
    OpenUrlPubMed
  38. ↵
    1. Zittermann A,
    2. Prokop S,
    3. Gummert JF,
    4. Börgermann J
    : Safety issues of vitamin D supplementation. Anticancer Agents Med Chem 13: 4-10, 2013.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Riley RD,
    2. Lambert PC,
    3. Abo-Zaid G
    . Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340: c221, 2010.
    OpenUrlFREE Full Text
  40. ↵
    1. Lindqvist PG,
    2. Epstein E,
    3. Landin-Olsson M,
    4. Ingvar C,
    5. Nielsen K,
    6. Stenbeck M,
    7. Olsson H
    . Avoidance of sun exposure is a risk factor for all-cause mortality: results from the Melanoma in Southern Sweden cohort. J Intern Med 276: 77-86, 2014.
    OpenUrlCrossRefPubMed
    1. Lin SW,
    2. Wheeler DC,
    3. Park Y,
    4. Spriggs M,
    5. Hollenbeck AR,
    6. Freedman DM,
    7. Abnet CC
    . Prospective study of ultraviolet radiation exposure and mortality risk in the United States. Am J Epidemiol 178: 521-533, 2013.
    OpenUrlCrossRefPubMed
    1. Yang L,
    2. Lof M,
    3. Veierød MB,
    4. Sandin S,
    5. Adami HO,
    6. Weiderpass E
    . Ultraviolet exposure and mortality among women in Sweden. Cancer Epidemiol Biomarkers Prev 20: 683-690, 2011.
    OpenUrlAbstract/FREE Full Text
    1. Rees J,
    2. Naysmith L
    . In this issue: To expose or not to expose? Acta Derm Venereol 90: 339, 2010.
    OpenUrlPubMed
    1. Zittermann A,
    2. Schleithoff SS,
    3. Frisch S,
    4. Götting C,
    5. Kuhn J,
    6. Koertke H,
    7. Kleesiek K,
    8. Tenderich G,
    9. Koerfer R
    . Circulating calcitriol concentrations and total mortality. Clin Chem 55: 1163-1170, 2009.
    OpenUrlAbstract/FREE Full Text
    1. Wolf M,
    2. Shah A,
    3. Gutierrez O,
    4. Ankers E,
    5. Monroy M,
    6. Tamez H,
    7. Steele D,
    8. Chang Y,
    9. Camargo CA Jr.,
    10. Tonelli M,
    11. Thadhani R
    . Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Keyzer CA,
    2. Riphagen IJ,
    3. Joosten MM,
    4. Navis G,
    5. Muller Kobold AC,
    6. Kema IP,
    7. Bakker SJ,
    8. de Borst MH,
    9. NIGRAM consortium
    . Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J Clin Endocrinol Metab 100: 81-9, 2015.
    OpenUrlPubMed
  42. ↵
    1. Wang TJ,
    2. Zhang F,
    3. Richards JB,
    4. Kestenbaum B,
    5. van Meurs JB,
    6. Berry D,
    7. Kiel DP,
    8. Streeten EA,
    9. Ohlsson C,
    10. Koller DL,
    11. Peltonen L,
    12. Cooper JD,
    13. O'Reilly PF,
    14. Houston DK,
    15. Glazer NL,
    16. Vandenput L,
    17. Peacock M,
    18. Shi J,
    19. Rivadeneira F,
    20. McCarthy MI,
    21. Anneli P,
    22. de Boer IH,
    23. Mangino M,
    24. Kato B,
    25. Smyth DJ,
    26. Booth SL,
    27. Jacques PF,
    28. Burke GL,
    29. Goodarzi M,
    30. Cheung CL,
    31. Wolf M,
    32. Rice K,
    33. Goltzman D,
    34. Hidiroglou N,
    35. Ladouceur M,
    36. Wareham NJ,
    37. Hocking LJ,
    38. Hart D,
    39. Arden NK,
    40. Cooper C,
    41. Malik S,
    42. Fraser WD,
    43. Hartikainen AL,
    44. Zhai G,
    45. Macdonald HM,
    46. Forouhi NG,
    47. Loos RJ,
    48. Reid DM,
    49. Hakim A,
    50. Dennison E,
    51. Liu Y,
    52. Power C,
    53. Stevens HE,
    54. Jaana L,
    55. Vasan RS,
    56. Soranzo N,
    57. Bojunga J,
    58. Psaty BM,
    59. Lorentzon M,
    60. Foroud T,
    61. Harris TB,
    62. Hofman A,
    63. Jansson JO,
    64. Cauley JA,
    65. Uitterlinden AG,
    66. Gibson Q,
    67. Järvelin MR,
    68. Karasik D,
    69. Siscovick DS,
    70. Econs MJ,
    71. Kritchevsky SB,
    72. Florez JC,
    73. Todd JA,
    74. Dupuis J,
    75. Hyppönen E,
    76. Spector TD
    . Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180-188, 2010.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Ahn J,
    2. Yu K,
    3. Stolzenberg-Solomon R,
    4. Simon KC,
    5. McCullough ML,
    6. Gallicchio L,
    7. Jacobs EJ,
    8. Ascherio A,
    9. Helzlsouer K,
    10. Jacobs KB,
    11. Li Q,
    12. Weinstein SJ,
    13. Purdue M,
    14. Virtamo J,
    15. Horst R,
    16. Wheeler W,
    17. Chanock S,
    18. Hunter DJ,
    19. Hayes RB,
    20. Kraft P,
    21. Albanes D
    . Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19: 2739-2745, 2010.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Verduijn M,
    2. Siegerink B,
    3. Jager KJ,
    4. Zoccali C,
    5. Dekker FW
    . Mendelian randomization: use of genetics to enable causal inference in observational studies. Nephrol Dial Transplant 25: 1394-1398, 2010.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Vimaleswaran KS,
    2. Cavadino A,
    3. Berry DJ,
    4. LifeLines Cohort Study investigators,
    5. Jorde R,
    6. Dieffenbach AK,
    7. Lu C,
    8. Alves AC,
    9. Heerspink HJ,
    10. Tikkanen E,
    11. Eriksson J,
    12. Wong A,
    13. Mangino M,
    14. Jablonski KA,
    15. Nolte IM,
    16. Houston DK,
    17. Ahluwalia TS,
    18. van der Most PJ,
    19. Pasko D,
    20. Zgaga L,
    21. Thiering E,
    22. Vitart V,
    23. Fraser RM,
    24. Huffman JE,
    25. de Boer RA,
    26. Schöttker B,
    27. Saum KU,
    28. McCarthy MI,
    29. Dupuis J,
    30. Herzig KH,
    31. Sebert S,
    32. Pouta A,
    33. Laitinen J,
    34. Kleber ME,
    35. Navis G,
    36. Lorentzon M,
    37. Jameson K,
    38. Arden N,
    39. Cooper JA,
    40. Acharya J,
    41. Hardy R,
    42. Raitakari O,
    43. Ripatti S,
    44. Billings LK,
    45. Lahti J,
    46. Osmond C,
    47. Penninx BW,
    48. Rejnmark L,
    49. Lohman KK,
    50. Paternoster L,
    51. Stolk RP,
    52. Hernandez DG,
    53. Byberg L,
    54. Hagström E,
    55. Melhus H,
    56. Ingelsson E,
    57. Mellström D,
    58. Ljunggren O,
    59. Tzoulaki I,
    60. McLachlan S,
    61. Theodoratou E,
    62. Tiesler CM,
    63. Jula A,
    64. Navarro P,
    65. Wright AF,
    66. Polasek O,
    67. International Consortium for Blood Pressure (ICBP),
    68. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium,
    69. Global Blood Pressure Genetics (Global BPGen) consortium,
    70. Hayward Caroline,
    71. Wilson JF,
    72. Rudan I,
    73. Salomaa V,
    74. Heinrich J,
    75. Campbell H,
    76. Price JF,
    77. Karlsson M,
    78. Lind L,
    79. Michaëlsson K,
    80. Bandinelli S,
    81. Frayling TM,
    82. Hartman CA,
    83. Sørensen TI,
    84. Kritchevsky SB,
    85. Langdahl BL,
    86. Eriksson JG,
    87. Florez JC,
    88. Spector TD,
    89. Lehtimäki T,
    90. Kuh D,
    91. Humphries SE,
    92. Cooper C,
    93. Ohlsson C,
    94. März W,
    95. de Borst MH,
    96. Kumari M,
    97. Kivimaki M,
    98. Wang TJ,
    99. Power C,
    100. Brenner H,
    101. Grimnes G,
    102. van der Harst P,
    103. Snieder H,
    104. Hingorani AD,
    105. Pilz S,
    106. Whittaker JC,
    107. Järvelin MR,
    108. Hyppönen E
    : Association of vitamin D status with arterial blood pressure and hypertension risk: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2: 719-729, 2014.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Vimaleswaran KS,
    2. Berry DJ,
    3. Lu C,
    4. Tikkanen E,
    5. Pilz S,
    6. Hiraki LT,
    7. Cooper JD,
    8. Dastani Z,
    9. Li R,
    10. Houston DK,
    11. Wood AR,
    12. Michaëlsson K,
    13. Vandenput L,
    14. Zgaga L,
    15. Yerges-Armstrong LM,
    16. McCarthy MI,
    17. Dupuis J,
    18. Kaakinen M,
    19. Kleber ME,
    20. Jameson K,
    21. Arden N,
    22. Raitakari O,
    23. Viikari J,
    24. Lohman KK,
    25. Ferrucci L,
    26. Melhus H,
    27. Ingelsson E,
    28. Byberg L,
    29. Lind L,
    30. Lorentzon M,
    31. Salomaa V,
    32. Campbell H,
    33. Dunlop M,
    34. Mitchell BD,
    35. Herzig KH,
    36. Pouta A,
    37. Hartikainen AL,
    38. Genetic Investigation of Anthropometric Traits-GIANT Consortium,
    39. Streeten EA,
    40. Theodoratou E,
    41. Jula A,
    42. Wareham NJ,
    43. Ohlsson C,
    44. Frayling TM,
    45. Kritchevsky SB,
    46. Spector TD,
    47. Richards JB,
    48. Lehtimäki T,
    49. Ouwehand WH,
    50. Kraft P,
    51. Cooper C,
    52. März W,
    53. Power C,
    54. Loos RJ,
    55. Wang TJ,
    56. Järvelin MR,
    57. Whittaker JC,
    58. Hingorani AD,
    59. Hyppönen E
    : Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med 10: e1001383, 2013.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Afzal S,
    2. Brøndum-Jacobsen P,
    3. Bojesen SE,
    4. Nordestgaard BG
    : Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ 349: g6330, 2014.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Bjelakovic G,
    2. Gluud LL,
    3. Nikolova D,
    4. Whitfield K,
    5. Wetterslev J,
    6. Simonetti RG,
    7. Bjelakovic M,
    8. Gluud C
    : Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 1: CD007470, 2014.
  49. ↵
    1. Rejnmark L,
    2. Avenell A,
    3. Masud T,
    4. Anderson F,
    5. Meyer HE,
    6. Sanders KM,
    7. Salovaara K,
    8. Cooper C,
    9. Smith HE,
    10. Jacobs ET,
    11. Torgerson D,
    12. Jackson RD,
    13. Manson JE,
    14. Brixen K,
    15. Mosekilde L,
    16. Robbins JA,
    17. Francis RM,
    18. Abrahamsen B
    : Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 97: 2670-2681, 2012.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Bolland MJ,
    2. Grey A,
    3. Gamble GD,
    4. Reid IR
    : The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2: 307-320, 2014.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Amrein K,
    2. Schnedl C,
    3. Holl A,
    4. Riedl R,
    5. Christopher KB,
    6. Pachler C,
    7. Urbanic Purkart T,
    8. Waltensdorfer A,
    9. Münch A,
    10. Warnkross H,
    11. Stojakovic T,
    12. Bisping E,
    13. Toller W,
    14. Smolle KH,
    15. Berghold A,
    16. Pieber TR,
    17. Dobnig H
    . Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA 312: 1520-1530, 2014.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Pilz S,
    2. Kienreich K,
    3. Tomaschitz A,
    4. Ritz E,
    5. Lerchbaum E,
    6. Obermayer-Pietsch B,
    7. Matzi V,
    8. Lindenmann J,
    9. März W,
    10. Gandini S,
    11. Dekker JM
    : Vitamin D and cancer mortality: systematic review of prospective epidemiological studies. Anticancer Agents Med Chem 13: 107-117, 2013.
    OpenUrlCrossRefPubMed
    1. Yin L,
    2. Ordóñez-Mena JM,
    3. Chen T,
    4. Schöttker B,
    5. Arndt V,
    6. Brenner H
    : Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Prev Med 57: 753-764, 2013.
    OpenUrlCrossRefPubMed
    1. Pilz S,
    2. Tomaschitz A,
    3. Obermayer-Pietsch B,
    4. Dobnig H,
    5. Pieber TR
    . Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res 29: 3699-3704, 2009.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Mohr SB,
    2. Gorham ED,
    3. Kim J,
    4. Hofflich H,
    5. Garland CF
    . Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res 34: 1163-1166, 2014.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Keum N,
    2. Giovannucci E
    : Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer 111: 976-980, 2014.
    OpenUrlCrossRefPubMed
    1. Bjelakovic G,
    2. Gluud LL,
    3. Nikolova D,
    4. Whitfield K,
    5. Krstic G,
    6. Wetterslev J,
    7. Gluud C
    : Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev 6: CD007469, 2014.
  55. ↵
    1. Feldman D,
    2. Krishnan AV,
    3. Swami S,
    4. Giovannucci E,
    5. Feldman BJ
    . The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14: 342-357, 2014.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Ford JA,
    2. MacLennan GS,
    3. Avenell A,
    4. Bolland M,
    5. Grey A,
    6. Witham M,
    7. for the RECORD Trial Group
    : Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr 100: 746-755, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Pilz S,
    2. Tomaschitz A,
    3. Drechsler C,
    4. Zittermann A,
    5. Dekker JM,
    6. März W
    : Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr Drug Targets 12: 88-96, 2011.
    OpenUrlCrossRefPubMed
    1. Muscogiuri G,
    2. Sorice GP,
    3. Ajjan R,
    4. Mezza T,
    5. Pilz S,
    6. Prioletta A,
    7. Scragg R,
    8. Volpe SL,
    9. Witham MD,
    10. Giaccari A
    : Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr Metab Cardiovasc Dis 22: 81-87, 2012.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Pilz S,
    2. Gaksch M,
    3. O'Hartaigh B,
    4. Tomaschitz A,
    5. März W
    : The role of vitamin D deficiency in cardiovascular disease: Where do we stand in 2013? Arch Toxicol 87: 2083-2103, 2013.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Theodoratou E,
    2. Tzoulaki I,
    3. Zgaga L,
    4. Ioannidis JP
    : Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 348: g2035, 2014.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Autier P,
    2. Boniol M,
    3. Pizot C,
    4. Mullie P
    : Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2: 76-89, 2014.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Kiely M,
    2. Cashman KD,
    3. on behalf of the ODIN Consortium
    . The ODIN project: development of food-based approaches for prevention of vitamin D deficiency throughout life. Nutr Bull 40: 235-246, 2015.
    OpenUrlCrossRef
  61. ↵
    1. Bogh MK
    : Vitamin D production after UVB: aspects of UV-related and personal factors. Scand J Clin Lab Invest Suppl 243: 24-31, 2012.
    OpenUrlPubMed
    1. Bogh MK,
    2. Schmedes AV,
    3. Philipsen PA,
    4. Thieden E,
    5. Wulf HC
    : A small suberythemal ultraviolet B dose every second week is sufficient to maintain summer vitamin D levels: a randomized controlled trial. Br J Dermatol 166: 430-433, 2012.
    OpenUrlPubMed
    1. Wacker M,
    2. Holick MF
    : Sunlight and vitamin D: a global perspective for health. Dermatoendocrinol 5: 51-108, 2012.
    OpenUrl
    1. Earthman CP,
    2. Beckman LM,
    3. Masodkar K,
    4. Sibley SD
    : The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 36: 387-396, 2012.
    OpenUrlCrossRefPubMed
  62. ↵
    1. Wicherts IS,
    2. Boeke AJ,
    3. van der Meer IM,
    4. van Schoor NM,
    5. Knol DL,
    6. Lips P
    : Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants: a randomized clinical trial. Osteoporos Int 22: 873-882, 2011.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Kupferschmidt K
    : Uncertain verdict as vitamin D goes on trial. Science 337: 1476-1478, 2012.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Pilz S,
    2. Rutters F,
    3. Dekker JM
    : Disease prevention: vitamin D trials. Science 338: 883, 2012.
    OpenUrlFREE Full Text
    1. Pilz S,
    2. Gaksch M,
    3. Kienreich K,
    4. Grübler M,
    5. Verheyen N,
    6. Fahrleitner-Pammer A,
    7. Treiber G,
    8. Drechsler C,
    9. Ó Hartaigh B,
    10. Obermayer-Pietsch B,
    11. Schwetz V,
    12. Aberer F,
    13. Mader J,
    14. Scharnagl H,
    15. Meinitzer A,
    16. Lerchbaum E,
    17. Dekker JM,
    18. Zittermann A,
    19. März W,
    20. Tomaschitz A
    : Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension 65: 1195-1201, 2015.
    OpenUrl
  65. ↵
    1. Jorde R,
    2. Grimnes G
    : Vitamin D and health: the need for more randomized controlled trials. J Steroid Biochem Mol Biol 148: 269-274, 2015.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 36 (3)
Anticancer Research
Vol. 36, Issue 3
March 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vitamin D and Mortality
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Vitamin D and Mortality
STEFAN PILZ, MARTIN GRÜBLER, MARTIN GAKSCH, VERENA SCHWETZ, CHRISTIAN TRUMMER, BRÍAIN Ó. HARTAIGH, NICOLAS VERHEYEN, ANDREAS TOMASCHITZ, WINFRIED MÄRZ
Anticancer Research Mar 2016, 36 (3) 1379-1387;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Vitamin D and Mortality
STEFAN PILZ, MARTIN GRÜBLER, MARTIN GAKSCH, VERENA SCHWETZ, CHRISTIAN TRUMMER, BRÍAIN Ó. HARTAIGH, NICOLAS VERHEYEN, ANDREAS TOMASCHITZ, WINFRIED MÄRZ
Anticancer Research Mar 2016, 36 (3) 1379-1387;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Vitamin D Metabolism and Classic Effects of Vitamin D
    • Vitamin D Status and Mortality
    • Vitamin D Genetics and Mortality
    • Vitamin D Supplementation and Mortality
    • Vitamin D and Specific Causes of Death
    • Outlook and Conclusion
    • Acknowledgements
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Association of serum vitamin D levels and dietary vitamin D intake with latent tuberculosis infection and long-term mortality: a population-based cohort study
  • Vitamin D: Current Guidelines and Future Outlook
  • Vitamin D Supplementation Trials Aimed at Reducing Mortality Have Much Higher Power When Focusing on People with Low Serum 25-Hydroxyvitamin D Concentrations
  • Biologic Effects of Light: An Enlighting Prospective
  • Google Scholar

More in this TOC Section

PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM “BIOLOGIC EFFECTS OF LIGHT” (Homburg/Saar, Germany)

  • Solar Simulators for Healthy Vitamin D Synthesis
  • Photocarcinogenesis and Skin Cancer Prevention Strategies
  • Prospective Investigation of 25(OH)D3 Serum Concentration Following UVB Narrow Band Phototherapy in Patients with Psoriasis and Atopic Dermatitis
Show more PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM “BIOLOGIC EFFECTS OF LIGHT” (Homburg/Saar, Germany)

Review

  • Mobile and Wireless Technologies for Gastrointestinal Cancer Treatment
  • De Novo Testicular Cancers Arising After Renal Transplantation: A Narrative Review
  • Adjuvant Treatment for Resectable Pancreatic Cancer
Show more Review

Similar Articles

Keywords

  • vitamin D
  • mortality
  • RCT
  • epidemiology
  • 25(OH)D
  • review
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire